NEARLY nineteen percent of patients with rheumatoid arthritis exhibit sarcopenia, worsened by corticosteroid dosage and disease chronicity. In a cross-sectional study evaluating 978 adults using the Asian Working Group for Sarcopenia 2025 consensus criteria, investigators identified an overall sarcopenia prevalence of 18.6%. Sarcopenia was defined by concurrent reductions in appendicular skeletal muscle mass measured via bioelectrical impedance analysis and low muscle strength measured through handgrip dynamometry. The cohort presented an average age of 60.1 years with an 86.4% female predominance, mirroring clinical populations treated for chronic autoimmune joint disorders.
Multivariable logistic regression revealed distinct phenotypic determinants of sarcopenia in rheumatoid arthritis. Male sex conferred a ninefold increase in odds (adjusted odds ratio: 9.140, 95% confidence interval: 5.211 to 16.029), reflecting potential endocrine variances and baseline skeletal differences. Lower body mass index emerged as an independent risk factor, demonstrating an adjusted odds ratio of 0.586. Each additional year of disease duration increased the odds of muscle depletion by 4.6%. Furthermore, elevated levels of IgM rheumatoid factor correlated with heightened risk (adjusted odds ratio: 1.002). While older age, erythrocyte sedimentation rate, and coexisting osteoporosis exhibited crude associations in unadjusted evaluations, these factors lost statistical significance after adjusting for baseline confounders.
Pharmacotherapy significantly modulated the prevalence of sarcopenia in rheumatoid arthritis. Current daily oral prednisone intake increased the risk of muscle loss, showing an adjusted odds ratio of 1.094 per milligram increase. Glucocorticoids activate catabolic gene expression, driving skeletal muscle protein breakdown regardless of inflammation suppression. Conversely, biologic therapies demonstrated substantial protective associations. Patients receiving tumor necrosis factor inhibitors experienced a 49.8% reduction in sarcopenia odds (adjusted odds ratio: 0.502). Similarly, treatment with the interleukin six receptor antagonist tocilizumab halved the odds of sarcopenia (adjusted odds ratio: 0.493). Methotrexate, nonsteroidal anti-inflammatory drugs, and Janus kinase inhibitors demonstrated no statistically significant correlation with muscle wasting in adjusted models.
These findings highlight the necessity of active surveillance for sarcopenia in rheumatoid arthritis. Physical function and muscle strength should be routinely monitored alongside joint inflammation, especially in men and individuals maintaining lower body weight. Clinicians should recognize that reliance on body mass index alone overlooks hidden lean mass loss. Tapering glucocorticoids to the lowest effective dosage while considering cytokine-targeted biologic regimens may help protect muscle integrity and minimize long-term frailty.
Reference
Wang H et al. Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study. RMD Open. 2026;12:e006945.
Featured Image: eyeonpark on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
